Perspective & Review
WANG Jiahui, GU Fenghua
Small interfering RNA(siRNA) is a programmable gene-silencing therapeutic agent that can
specifically downregulate the expression of pathogenic genes through the RNA interference mechanism, thereby exhibiting
significant potential in precision therapy for respiratory diseases. In recent years, siRNA agents targeting key pathogenic
genes in respiratory diseases have shown promising therapeutic efficacy in disease models such as lung cancer, asthma,
COPD, and idiopathic pulmonary fibrosis. However, naked siRNA suffers from several limitations, including poor in vivo
stability, high susceptibility to nuclease degradation, low transmembrane delivery efficiency, difficulty in penetrating the
pulmonary mucus barrier, and inadequate endosomal escape capability, which severely hinder its clinical translation. To
address these challenges, various nanoscale delivery systems, including lipid nanoparticles, polymeric nanoparticles, viral
vectors, inorganic nanomaterials, and exosomes, have been developed for the efficient delivery of siRNA to pulmonary
lesions. Centered on the “disease - siRNA target - delivery system” framework, this review systematically summarizes the
research progress of representative siRNA-based nanoscale delivery systems for respiratory diseases. It critically examines
how different nanocarriers influence siRNA delivery efficiency with respect to systemic circulation stability, pulmonary
targeting, mucus penetration, cellular uptake, and endosomal escape. Furthermore, it outlines optimization strategies such as
passive targeting, ligand modification, stimuli-responsiveness, and biomimetic modification, aiming to provide a reference
for further research and clinical translation of siRNA therapeutics for lung-targeted treatment of respiratory diseases.